Recombinant TAT–gelonin fusion toxin: Synthesis and characterization of heparin/protamine‐regulated cell transduction. Issue 1 (23rd April 2014)
- Record Type:
- Journal Article
- Title:
- Recombinant TAT–gelonin fusion toxin: Synthesis and characterization of heparin/protamine‐regulated cell transduction. Issue 1 (23rd April 2014)
- Main Title:
- Recombinant TAT–gelonin fusion toxin: Synthesis and characterization of heparin/protamine‐regulated cell transduction
- Authors:
- Shin, Meong Cheol
Zhao, Jingwen
Zhang, Jian
Huang, Yongzhuo
He, Huining
Wang, Mei
Min, Kyoung Ah
Yang, Victor C. - Abstract:
- <abstract abstract-type="main"> <title>Abstract</title> <p>Protein toxins, such as gelonin, are highly desirable anti‐cancer drug candidates due to their unparalleled potency and repetitive reaction mechanism in inhibiting protein translation. However, for its potential application in cancer therapy, there remains the cell membrane barrier that allows permeation of only small molecules, which must be overcome. To address this challenge, we conjugated gelonin with a protein transduction domain (PTD), the TAT peptide, via genetic recombination. The chimeric TAT–gelonin fusion protein (TAT‐Gel) retained equipotent <italic>N</italic>‐glycosidase activity yet displayed greater cell uptake than unmodified recombinant gelonin (rGel), thereby yielding a significantly augmented cytotoxic activity. Remarkably, TAT‐Gel displayed up to 177‐fold lower IC<sub>50</sub> (avg. 54.3 n<italic>M</italic>) than rGel (avg. IC<sub>50</sub>: 3640 n<italic>M</italic>) in tested cell lines. This enhanced cytotoxicity, however, also raised potential toxicity concerns due to the non‐selectivity of PTD in its mediated cell transduction. To solve this problem, we investigated the plausibility of regulating the cell transduction of TAT‐Gel via a reversible masking using heparin and protamine. Here, we demonstrated, both <italic>in vitro</italic> and <italic>in vivo</italic>, that the cell transduction of TAT‐Gel can be completely curbed with heparin and yet this heparin block can be efficiently reversed<abstract abstract-type="main"> <title>Abstract</title> <p>Protein toxins, such as gelonin, are highly desirable anti‐cancer drug candidates due to their unparalleled potency and repetitive reaction mechanism in inhibiting protein translation. However, for its potential application in cancer therapy, there remains the cell membrane barrier that allows permeation of only small molecules, which must be overcome. To address this challenge, we conjugated gelonin with a protein transduction domain (PTD), the TAT peptide, via genetic recombination. The chimeric TAT–gelonin fusion protein (TAT‐Gel) retained equipotent <italic>N</italic>‐glycosidase activity yet displayed greater cell uptake than unmodified recombinant gelonin (rGel), thereby yielding a significantly augmented cytotoxic activity. Remarkably, TAT‐Gel displayed up to 177‐fold lower IC<sub>50</sub> (avg. 54.3 n<italic>M</italic>) than rGel (avg. IC<sub>50</sub>: 3640 n<italic>M</italic>) in tested cell lines. This enhanced cytotoxicity, however, also raised potential toxicity concerns due to the non‐selectivity of PTD in its mediated cell transduction. To solve this problem, we investigated the plausibility of regulating the cell transduction of TAT‐Gel via a reversible masking using heparin and protamine. Here, we demonstrated, both <italic>in vitro</italic> and <italic>in vivo</italic>, that the cell transduction of TAT‐Gel can be completely curbed with heparin and yet this heparin block can be efficiently reversed by the addition of protamine. This reversible tight regulation of the cell transduction of TAT‐Gel by heparin and protamine sheds light of possible application of TAT‐Gel in achieving a highly effective yet safe drug therapy for the treatment of tumors. © 2014 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 103A: 409–419, 2015.</p> </abstract> … (more)
- Is Part Of:
- Journal of biomedical materials research. Volume 103:Issue 1(2015:Jan.)
- Journal:
- Journal of biomedical materials research
- Issue:
- Volume 103:Issue 1(2015:Jan.)
- Issue Display:
- Volume 103, Issue 1 (2015)
- Year:
- 2015
- Volume:
- 103
- Issue:
- 1
- Issue Sort Value:
- 2015-0103-0001-0000
- Page Start:
- 409
- Page End:
- 419
- Publication Date:
- 2014-04-23
- Subjects:
- Biomedical materials -- Periodicals
610.28 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1552-4965 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/jbm.a.35188 ↗
- Languages:
- English
- ISSNs:
- 1549-3296
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4953.720000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3633.xml